NAV® rAAV Vectors

REGENX proprietary technology uses recombinant adeno-associated viral (rAAV) vectors for the delivery of new genetic materials to cells. rAAVs are uniquely designed by nature to effectively deliver genetic material to host cells.

REGENX NAV® rAAV Vector Technology has been developed through substantial investment in research and development to address the requirements of using viral vectors in vivo, R&D which has resulted in platforms that are optimized to provide significant advantages over other existing methods.

Advantages of “traditional” rAAV:

  • Non-pathogenic
  • Non-replicating
  • Efficient for delivering genes in vivo

REGENX NAV® Technology provides further advantages beyond “traditional” rAAV including:

  • Faster onset of gene expression
  • Long-lasting, stable gene expression
  • High tissue selectivity
  • High titer manufacture

For more information about the applications of REGENX NAV Technology, please visit these pages: